Skip to main content
XERS
NASDAQ Life Sciences

Xeris Biopharma Q2 Revenue Jumps 29% to $92M, Tightens 2026 Guidance to $385M–$390M

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$7.694
Mkt Cap
$1.4B
52W Low
$5.25
52W High
$10.08
52W Position info
47% above low
Off High info
24% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

XERS sits 47% above its 52-week low of $5.25.

Summary

Xeris Biopharma reported Q2 2026 revenue of $92.1 million, a 29% increase year-over-year, and tightened full-year revenue guidance to $385–$390 million. Recorlev led growth with an 81% revenue jump, while a non-cash charge from a convertible notes exchange resulted in a net loss.


Key Events · Earnings and Guidance · XERS

  • Q2 Revenue Beats, Guidance Tightened

    Total revenue reached $92.1 million, up 29% year-over-year, with net product revenue of $91.0 million (+34%). Full-year 2026 revenue guidance was tightened to $385–$390 million.

  • Recorlev Drives Growth

    Recorlev net revenue surged 81% to $56.8 million, reflecting strong patient demand and commercial execution.

  • Non-Cash Charge Hits Net Income

    A $31 million non-cash charge from the convertible notes exchange agreements led to a net loss of $31.1 million, though adjusted EBITDA was $19.3 million.

  • Patent Allowances Strengthen IP

    The USPTO issued a Notice of Allowance for a new Keveyis patent extending protection through at least 2039, and granted a second patent for XP-8121.


Analysis · XERS · Life Sciences

A strong second quarter saw total revenue climb 29% to $92.1 million, fueled by an 81% surge in Recorlev sales. Confidence in the trajectory prompted management to tighten full-year 2026 revenue guidance to $385–$390 million. While a one-time non-cash charge of $31 million from the convertible notes exchange pushed the bottom line to a net loss, adjusted EBITDA improved to $19.3 million. The results, together with new patent allowances for Keveyis and XP-8121, reinforce both the commercial and pipeline narrative, though the net loss and recent insider selling warrant attention.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, XERS was trading at $7.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $5.25 to $10.08. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

XERS - Latest Insights

XERS
Nov 05, 2026, 4:08 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $12.67
Real-time Price: $17.00 info
Change: +$4.33 (+34%) info
Market Cap: $3.1B info
XERS
Nov 05, 2026, 2:22 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $13.17
Real-time Price: $17.00 info
Change: +$3.84 (+29%) info
Market Cap: $3.1B info
XERS
Nov 05, 2026, 7:12 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $11.48
Real-time Price: $17.00 info
Change: +$5.52 (+48%) info
Market Cap: $3.1B info
XERS
Nov 05, 2026, 7:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $10.75
Real-time Price: $17.00 info
Change: +$6.25 (+58%) info
Market Cap: $3.1B info
XERS
Nov 05, 2026, 7:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $10.48
Real-time Price: $17.00 info
Change: +$6.52 (+62%) info
Market Cap: $3.1B info